Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, lifethreatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody ® , is effective for treating aTTP episodes and is well tolerated.
| INTRODUC TI ON
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare thrombotic microangiopathy, characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and organ ischemia, caused by a deficiency in ADAMTS13 activity. 1, 2 The lack of ADAMTS13 activity means ultra-large multimers of von Willebrand factor (vWF) are no longer adequately processed and cleaved. This allows unrestrained vWF-mediated platelet adhesion in the microvasculature, 3, 4 which, if left untreated, is fatal in >90% of cases. 3, 5 Although daily therapeutic plasma exchange (TPE) and immunosuppression has improved patient outcomes, acute mortality is still ~10% to 20%, [6] [7] [8] [9] [10] [11] [12] and patients are at risk for irreversible organ damage. 1, 9, 12, 13 In addition, 30%-50% of patients experience disease exacerbations 14 (platelet count <150 × 10 9 /L after initial recovery and within 30 days of last TPE 15 ), which may require rehospitalization and resumption of TPE, and puts patients at risk for thrombotic events and death associated with active disease. aTTP also has a tendency to relapse (recurrent disease >30 days after last TPE 14 ) if ADAMTS13 activity is severely deficient, 1, 4 with relapse rates of ~35% to 40% 6, 16 within the first 2 years, each relapse carrying a risk of morbidity and mortality.
Caplacizumab is a bivalent, humanized, single-variable-domain immunoglobulin or Nanobody ® targeting the A1 domain of vWF, 17 preventing interaction between vWF and platelets, and formation of microvascular thrombi. HERCULES (NCT02553317) was an international phase 3, randomized, double-blind, multicenter, placebo-controlled trial showing that caplacizumab was effective in treating aTTP, significantly shortening the time to normalization of platelet count versus placebo, and reducing the incidence of the composite endpoint (mortality, exacerbations, and major thromboembolic events during the treatment period) by 74% and the overall number of TTP exacerbations/relapses by 67%. 18 In HERCULES, caplacizumab had an acceptable safety profile; mild-to-moderate mucocutaneous bleeding was the most frequent treatment-emergent adverse event (TEAE). 18 Here we report the efficacy and safety outcomes of patients treated with open-label caplacizumab following an exacerbation during the double-blind treatment phase.
| ME THODS
Detailed methods of the HERCULES study have been published. 18 Briefly, adults with clinically diagnosed aTTP and one prior TPE treatment were randomized to caplacizumab (10 mg intravenous loading dose followed by daily 10 mg subcutaneous doses) or placebo, plus daily TPE and glucocorticoids. Other immunosuppressive therapies were permitted as per local practice. Treatment with caplacizumab continued until 30 days after TPE cessation and could be extended, on a weekly basis (4 weeks maximum), based on the presence of risk factors for recurrence, such as persistent severely Results: Thirty-one patients (placebo, n = 28; caplacizumab, n = 3) had an exacerbation during double-blind treatment. Twenty-eight patients switched to open-label caplacizumab (placebo, n = 26; caplacizumab, n = 2); the three others discontinued upon exacerbation. Median time to platelet count response (≥150 × 10 9 /L) was 3.49 days upon receiving caplacizumab. There were no deaths. During open-label treatment, further exacerbation or a major thromboembolic event (vena cava thrombosis) was experienced by one patient (3.6%) each. Consistent with the double-blind phase, the most frequent treatment-emergent adverse events were catheter site hemorrhage (28.6%), headache (21.4%), and epistaxis (17.9%).
Conclusions:
These results suggest that caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a disease exacerbation during doubleblind treatment in HERCULES. 
| RE SULTS AND D ISCUSS I ON
Twenty-eight patients in the placebo group and three in the caplacizumab group experienced an exacerbation during the double-blind treatment period (range: 2 to 25 days after daily TPE cessation).
Twenty-five of 28 patients in the placebo group had ADAMTS13 activity <10% at the time of exacerbation, indicative of unresolved immunological disease (Table 1 ). In the caplacizumab group, all three had an ADAMTS13 activity of <10%. Two patients had an infection likely contributing to the exacerbation, while the third was noncompliant with therapy (Table 1) . reported "suspected drug induced/infection-related TTP exacerbation" (verbatim term), suggestive of an infection-induced thrombocytopenia, and was corroborated by a normal ADAMTS13 of 78% at the time of exacerbation. Two other placebo patients had an ADAMTS13 of 11% and 64%. c In two patients, an infection may have triggered the thrombocytopenia: in one patient the TTP exacerbation was reported as "Suspected infection associated TTP exacerbation," with an adverse event of "device-related sepsis (catheter-associated bloodstream infection" reported on the day preceding the exacerbation. The other patient also had findings suggestive of an infection (ie, increase in C-reactive protein levels and increases in leukocytes and neutrophils). The third patient was noncompliant with therapy while having low ADAMTS13 (patient discontinued at time of exacerbation). d Platelet response defined as an initial platelet count ≥150 × 10 9 /L with subsequent stop of daily TPE within 5 days. e Patient was clinically well and had mild thrombocytopenia at 149 × 10 9 /L, while ADAMTS13 activity was normal at 60% and leukocyte and neutrophil counts were mildly elevated, suggestive of subclinical infection. Open-label caplacizumab was permanently withdrawn, as per protocol. Exacerbations of aTTP not only re-expose patients to the increased risk of morbidity and mortality, 16, 20 they also lead to readmission and resumption of daily TPE, and its complications. 21, 22 Thus, prevention of exacerbations is paramount. In patients who experience an exacerbation, prompt resolution of the episode is required to prevent further complications. Exacerbation rates during the double-blind period of HERCULES was substantially lower in the caplacizumab versus placebo group (4% versus 38%), 18 and was as- 
